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Abstract
Background: Drug resistance of falciparum malaria is a global problem. Sulphadoxine/pyrimethamine-resistant and
mefloquine-resistant strains of falciparum malaria have spread in Southeast Asia at lightning speed in 1980s-1990s,
and the Cambodia-Thailand border is one of the malaria epidemic areas with the most severe forms of multi-drug
resistant falciparum malaria.
Methods: Artemisinin-piperaquine (AP), dihydroartemisinin-piperaquine phosphate (DHP) and artemether-
lumefantrine (AL) were used to treat 110, 55 and 55 uncomplicated malaria patients, respectively. The total dosage
for adults is 1,750 mg (four tablets, twice over 24 hours) of AP, 2,880 mg (eight tablets, four times over two days)
of DHP, and 3,360 mg (24 tablets, six times over three days) of AL. The 28-day cure rate, parasite clearance time,
fever clearance time, and drug tolerance of patients to the three drugs were compared. All of the above methods
were consistent with the current national guidelines.
Results: The mean parasite clearance time was similar in all three groups (66.7 ± 21.9 hrs, 65.6 ± 27.3 hrs, 65.3 ±
22.5 hrs in AP, DHP and AL groups, respectively), and there was no remarkable difference between them; the fever
clearance time was also similar (31.6 ± 17.7 hrs, 34.6 ± 21.8 hrs and 36.9 ± 15.4 hrs, respectively). After following up
for 28-days, the cure rate was 95.1%(97/102), 98.2%(54/55) and 82.4%(42/51); and the recrudescence cases was
4.9%(5/102), 1.8%(1/55) and 17.6%(9/51), respectively. Therefore, the statistical data showed that 28-day cure rate in
AP and DHP groups was superior to AL group obviously.
The patients had good tolerance to all the three drugs, and some side effects (anoxia, nausea, vomiting, headache
and dizziness) could be found in every group and they were self-limited; patients in control groups also had good
tolerance to DHP and AL, there was no remarkable difference in the three groups.
Conclusions: AP, DHP and AL all remained efficacious treatments for the treatment of falciparum malaria in
Cambodia-Thailand border area. However, in this particular setting, the AP regimen turned out to be favourable in
terms of efficacy and effectiveness, simplicity of administration, cost and compliance.
Trial Registration: The trial was registered at Chinese Clinical Trial Register under identifier 2005L01041.
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Malaria kills around one million people each year,
although is a preventable and treatable infectious disease
[1]. Because malaria is a disease that affects mostly poor
and vulnerable population, it perpetuates a vicious cycle
of poverty in the developing world. Malaria can be pre-
vented, diagnosed and treated with a combination of
available tools. However, it has been estimated that USD
4.2 billion is needed each year to fully fund the fight
against malaria [2].
Drug resistant falciparum malaria is a global problem.
Sulphadoxine/pyrimethamine and mefloquine resistant
strains of falciparum parasites have spread quickly
throughout Southeast Asia in 1980s-1990s, and the
Cambodia-Thailand border is one of the endemic
regions with the most severe multi-drug resistant falci-
parum malaria [3-6]. WHO has recommended the use
of artemisinin combination therapy (ACT) to improve
anti-malarial effectiveness and to keep the selection of
drug-resistant parasites to a minimum [7]. Now more
than 60 countries have switched to ACT for treating
malaria, however, the wide-spread application of ACT
has been limited by high cost [8,9].
Dihydroartemisinin-piperaquine phosphate in a fixed-
dose preparation of dihydroartemisinin 40 mg and
piperaquine phosphate 320 mg has been shown to be
highly effective in treating falciparum malaria with an
efficacy of over 90% in China, Vietnam, and Cambodia
[10-12]. Artemether-lumefantrine (20 mg of artemether
and 120 mg of lumefantrine) is another ACT that is
administered in six consecutive doses: four tablets each
at 0 hours and 8 hours on the first day, then twice daily
on the two consecutive days. Lumefantrine is a highly
lipophilic substance, and the oral bioavailability varies
considerably among individuals, and increases greatly if
the drug is administered after a meal rich in fat [13].
This remains a limitation to the effective usage of the
drug because uptake may be reduced in fasting patients.
Artemisinin-piperaquine was recently developed by
Chinese scientists and has shown good efficacy and
safety in a two-day treatment course [14]. Piperaquine is
a 4-chloroquinoline (1,3-bis[1-(7-chloro-4’-quinolyl)-4’-
piperazinyl]) and was used to replace chloroquine in
China in 1970s-1980s. It has been shown that patients’
tolerance to piperaquine was better than to piperaquine
phosphate. Additionally, piperaquine can reduce the
treatment time and cost [9,15].
The pharmacodynamics studies of artemisinin and its
derivatives have shown that artemisinin (ART) and its
derivatives are characterized by a quick absorption, wide
distribution and quick excretion in vivo [16]. Clinical
trials of ART in the treatment of uncomplicated falci-
parum malaria, conducted in 2002 (Li Guoqiao and
others, unpublished data) showed that ART could
quickly inhibit the growth of parasite at the dosage of 2
mg/kg with no significant difference in the parasite
clearance time betweem ART and dihydroartemisinin
(DHA) at the same dosage. DHA is the active metabolite
of artemether and artesunate, which are widely used,
and ART derivative must be given for 7 days for opti-
mum cure rate if administered alone. Therefore, com-
bining an ART derivative with another anti-malarial
drug with a long half-life will shorten treatment time
and is considered the treatment of choice for falciparum
malaria [8,17].
In this trial, the effectiveness and safety of the three
drugs for the treatment of uncomplicated falciparum
malaria were compared and evaluated for developing an
optimal anti-malarial regimen.
Methods
Study site and recruitment procedures
The trial was conducted in Pursat Referral Hospital,
Pursat province, Cambodia. Pursat is located in the wes-
tern part of the country bordering Thailand. It is located
between the Tonle Sap lake and the northern end of the
Cardamom Mountains. The patients for this trial came
from the forest area in the Cambodia and Thailand
boarder, where multi-drug resistant falciparum malaria
is widespread.
The implementation of this study is according to the
“Agreement of Cambodia-China Fast Malaria Control
Co-operation” and “National Ethics Committee for
Health Research (No.03G/03NECHR)” signed by
Guangzhou University of Chinese Medicine, China, and
the Ministry of Health, Kingdom of Cambodia.
Enrolment
It was a prospective, open labeled, randomized con-
trolled trial conducted on patients with microscopically
confirmed symptomatic of falciparum malaria, between
seven and 65 years of age. All patients with symptoms
of malaria, such as fever, and who had not been admi-
nistrated any anti-malarial drug, including sulphona-
mide, tetracycline or trimethoprim, in the previous
week, were enrolled [18]. A standard data sheet was
used to record demographic information, details of
symptoms and their duration, and anti-malarial history.
Clinical examination, vital signs and axillary tempera-
ture were documented. Giemsa-stained thick and thin
blood films were used to confirm parasite species and
parasitaemia.
Inclusion criteria: (1) patients with clinical symptoms
of malaria, such as fever (axillary temperature≥37.5°C),
(2) age ranged from seven to 65 years, (3) peripheral
blood smears showed that falciparum malaria asexual
parasite were 1,000~100,000/μl, (4) no anti-malarial had
been taken within seven days prior to the onset of
Song et al. Malaria Journal 2011, 10:231
http://www.malariajournal.com/content/10/1/231
Page 2 of 8symptoms or admission, including sulphonamide, tetra-
cycline or trimethoprim.
Exclusion criteria: (1) pregnant women;(2) lactating
mothers; (3) children under seven years of age, senior
persons elder than 65 years of age; (4) patients with
severe vomiting or diarrhoea, or other signs of severe
malaria; (5) febrile diseases other than falciparum
malaria; (6) exiting before the 28-day follow up and/or
lack of follow-up data; (7) patients identified as re-infec-
tion by PCR were also excluded from the final cure rate
and recrudescence rate calculation.
Randomization and masking
Patients were allocated to three treatment arms based
on a pre-generated randomization list made in blocks of
20 that was produced and held independently of the
field teams by a statistician. The individual allocations
were kept in sealed, opaque envelopes and opened only
after enrolment by the field team. Patients and clinical
field workers were not blinded to the treatment arm
after allocation. Microscopists were blinded to treatment
allocation at follow-up examinations. Adverse events
were assessed by symptom enquiry at every visit.
Drugs and regimen
AP tablets containing 62.5 mg artemisinin (ART) and
375 mg piperaquine (PQ) per tablet were provided by
Artepharm Co., Ltd., China (batch No. was 20030820).
DHP tablets containing 40 mg dihydroartemisinin
(DHA) and 375 mg piperaquine phosphate (PQP) were
provided by Guangzhou Holleykin Pharmaceutical Co.,
Ltd. (batch No. was 20030301). AL tablets containing 20
mg artemether and 120 mg lumefantrine were obtained
from Beijng Novartis Pharm Ltd. (batch No. was
20030822). The regimens of AP, DHP and AL were
listed in Additional file 1, Table S1.
Follow-up
At enrollment, a full physical examination, including a
neurological examination and a medical history, was
performed. Thick and thin blood smears were examined
by microscopy, and routine haematology was performed.
Drug administration was observed by study physicians.
If vomiting occurred within 1 h of dosing, the medica-
tions were re-administrated. The patients were kept in
the hospital for 7 days or until parasites were cleared
and were followed-up weekly till D28 from the start of
treatment or whenever he/she felt sick within 28 days.
At each follow-up, blood smear was done via a finger
prick. Blood spots were collected from those with reap-
pearance of asexual parasitaemia. All information was
recorded on a standard case record form.
Sample size
A total of 245 cases of uncomplicated malaria were
enrolled for this study. The patients were separated into
t h r e er a n d o mg r o u p sw i t h1 2 2c a s e si nA Pg r o u p ,6 1
cases in DHP group and 62 cases in AL groups. And
complete data from 110, 55 and 55 patients, respec-
tively, were obtained and analyzed.
Laboratory tests and outcome measurement
Patients were observed in the hospital for 7 days and
followed up at D14, D21 and D28 for any symptoms or
malaria parasites changes. Temperature was taken every
six hours and once daily after it returned to normal
(37.5°C) for 24 hours. Ward rounds were done twice
daily in the morning and afternoon, and side effects
were inquired and recorded according to the “Side
Effects Record Form”.
Thick and thin blood smears were taken at 7 AM and
5 PM from D0 to D4 to calculate the number of asexual
form per 200 WBCs (White Blood Cells). If the number
of parasites < 1/200 WBC, 200 fields were examined to
identify parasite clearance. Three consecutive negative
blood smears (from D5 to D7) indicated clearance of
parasite. For follow-ups, blood smears were taken at
D14, D21 and D28 to investigate recrudescence. If a
patient had fever, he or she was advised to go back to
the hospital for further examination. Blood spots col-
lected D0 and positive blood smears during 28-day fol-
low up were kept for qualitative PCR analysis. Blood
spots of patients whose blood smears were positive
within 28-day follow up were sent to the Oxford Uni-
versity Clinical Research Unit, Hospital for Tropical Dis-
eases, Ho Chi Minh City, Vietnam, for PCR qualitative
analysis to differentiate re-infection and recrudescence.
WBC and RBC (Red Blood Cell) counts and electro-
cardiogram examination were done at D0 and D7. Ala-
nine aminotransferase (ALT), aspartate aminotransferase
(AST), total bilirubin (TBIL), direct bilirubin (DBIL),
creatinine (CR) and blood urea nitrogen(BUN)were also
examined at D0 and D7. Abnormal items found at D7
were re-examined every week until the patient
recovered.
The following four main efficacy parameters were
used: Early Treatment Failure (ETF); Late Clinical Fail-
ure (LCF); Late Parasitological Failure (LPF); Adequate
Clinical and Parasitological Response (ACPR) [18]. The
o c c u r r e n c er a t eo fs i d ee f f e c t s( a n ys y m p t o m sa n d
objective sign having appeared or aggravated after the
administration) was recorded. Functions of liver and
kidney and electrocardiogram before and after drug
administration were checked in order to evaluate the
toxicity and side effects of drug to the major organs.
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The patients in the trial continued to live in the area of
transmission, therefore, re-infection during the four
weeks of follow-up was possible. Then, PCR-genotyping
were used to distinguish recrudescence from re-infec-
tion. Blood samples were taken at baseline (D0) and on
the day of reappearance of parasitaemia [1]. The nested
PCR of three polymorphic marker genes [Merozoite
Surface Antigen-1 (MSA-1), Merozoite Surface Antigen-
1 (MSA-2), and Glutamine-rich Protein (GLURP)] were
conducted in University of Oxford Clinical Research
Unit, Hospital for Tropical Diseases, Ho Chi Minh City,
Vietnam. PCR products were analyzed by agarose gel
electrophoresis. Patients with the same parasite PCR
profiles in the first and second infections were consid-
ered to have a recrudescent infection.
Statistical analysis
Statistic analysis was conducted using SAS 6.12. Data
were presented as means ± standard deviation (SD) or
as the geometric mean and range. All statistical tests
were two-tailed, and a significance level of 0.05 was
used.
Ethical approval
The study was approved by the National Ethics Com-
mittee for Health Research of the Ministry of Health,
Phnom Penh, Kingdom of Cambodia, and the Ethics
Committee of Guangzhou University of Chinese Medi-
cine, Guangzhou, China. This ethics approval of the trial
describes recruitment of patients with uncomplicated
infection with P. falciparum, with treatments for AP,
DHP and AL, then research on the therapeutic efficacy
and safety. The clinical trials registry number was
2005L01041.
Results
Patient recruitment and participant flow
From 22 July, 2005 to 18 October, 2005, 220 patients
completed in the study with 110 receiving AP, 55 receiv-
ing DHP and 55 receiving AL (Figure 1). Common rea-
sons for exclusion included lack of follow-up data, and
patients exiting before the 28-day follow up. Among the
220 patients completing the clinical trial, 18 (8.18%)
were 7-10 years of age, 26 (11.82%) were 11-15 years of
age, and 176 (80.00%) were more than 15 years old. A
flow chart of patient enrollment procedures and treat-
ment is shown in Figure 1. Baseline characteristics of
the recruited patients are similar, and it is shown in
Table 1.
Treatment effectiveness
There was no early treatment failure in the first three
day following initiation of therapy for all the patients
with 28-day follow up data. The Adequate Clinical and
Parasitological Response (ACPR) of the three groups on
D28 were 97/110 (88.2%), 54/55 (98.2) and 42/55
(76.4%), respectively (Table 2). During the 28-day follow
up, blood smears of 13 cases were found positive in the
AP group. According to the results of PCR qualitative
analysis, eight cases were classified as re-infection and
five cases were recrudescence (one case recrudesced at
D21 and four cases recrudesced at D28). In the DHP
group, one blood smear was found positive at D28, and
it was identified as recrudescence according to the qua-
litative PCR analysis. Among the 13 blood smear posi-
tive cases in the AL group, four cases were considered
re-infection and nine cases were recrudescence (one
case recrudesced at D14, three cases at D21 and five
cases at D28).
The 28-day cure rates adjusted after PCR analysis
were 97/102 (95.1%), 54/55(98.2%), 42/51 (82.4%) for
AP, DHP and AL, respectively (Table 2). There was no
significant difference between AP and DHP (P > 0.05).
T h e2 8 - d a yc u r er a t ei nt h eA Pg r o u pw a ss i g n i f i c a n t l y
higher than that in the AL group (P < 0.05) (Table 2).
The parasite and fever clearance time in the three
groups were similar (P > 0.05) (Table 2).
Side effects
T h e r ew e r en os e r i o u sa d v e r s ee v e n t sr e c o r d e dd u r i n g
the trial. All of the three study drugs appeared to be
well tolerated.
Haematology, electrocardiogram and biochemistry
No abnormal changes in haemotology and electrocardio-
gram were observed in the three study groups. Slightly
increases in AST, ALT, BIL, BUN and CR measure-
ments were found at D0 in all three groups, and most
of them returned to normal ranges at D7. At D7, there
were two cases with high TBIL in the AP group, one
case with high AST and two cases with high CR, but
they became normal at D14. There were four cases with
high CR in the DHP group at D7; again they became
normal at D14. There were two cases with high TBIL,
three cases with high AST and one case with high BUN
in the AL group at D7, and they returned normal at
D14.
Discussion
This randomized clinical trial showed that both AP
and DHP were highly efficacious in clearing parasitae-
mia and were well tolerated for treatment of uncompli-
cated malaria in the Cambodia-Thailand border. Lower
cure rate was obtained from AL treatment (Figure 2),
which was similar to the results reported previously
(71.1% cure rate in 2002 and 86.5% in 2003) [19]. The
reason may be that, the lack of fat in the patient diet
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partner drugs in AL. Dietary fat had been shown to
enhance the bioavailability of artemether and lumefan-
trine, although this effect was more apparent for lume-
fantrine [13,20,21]. Administration of AL to healthy
volunteers at the same time as a high-fat meal
increases the bioavailability of artemether and lumefan-
trine by two-fold and 16-fold, respectively, compared
with the fasting state [13,21].
No obvious side effects related to the drugs were
found in all the three groups. Although symptoms of
anoxia, nausea, vomiting, headache and dizziness were
observed in some patients, which was similar to those
observed in Chinese healthy volunteers and in Vietna-
mese patients, as well as in Rwandan children
[10,22-26]. The occurrence rate of side effects was low.
Comparing the results of haematology, biochemistry
and electrocardiogram between those before and after
drug administration showed no obvious toxic reactions
related to drugs. The patients in the three groups had
good tolerance to the drugs. Although more side
effects caused by piperaquine phosphate in DHP than
N= 220 Patients enrolled and randomized 
n = 110 
AP 
n = 55 
DHP 
n = 55 
AL 
Completed 
28-days follow 
up 110 (100%) 
Completed 
28-days follow 
up 55 (100%) 
Completed 
28-days follow 
up 55 (100%) 
Reinfection 
n = 8 
Recrudecence 
n = 5   
Reinfection 
n = 0 
Recrudecence 
 n  =  1 
Reinfection 
n = 4   
Recrudecence 
 n  =  9 
1000 patients presenting to clinics: 
680 active visit; 320 outpatients 
641 negative by microscopy 
359 positive by microscopy 
84 P. vivax ,30 mixed infections 
245 P. falciparum 
25 refused or unable to follow-up 
Figure 1 Patients flow chat in the clinical trial.
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reported previously [27,28], the data presented here
did not show any differences in the two groups. In
1998, WHO launched Roll Back Malaria campaign,
which aimed to reduce the global number of deaths
due to malaria in half by 2010 [7]. However, until
2004, the global number of people having died of
malaria had not declined, because the high prices of
ACT have delayed timely drug distribution [16,18]. In
East Africa, failure rates of chloroquine and sulphadox-
ine-pyrimethamine treatment were 64% and 45%,
respectively, and children deaths due to malaria
increased by 11-fold [8,29]. Therefore, it is imminent
to develop affordable ACT, that is cheaper for people
in malaria-endemic countries.
The 28-day cure rate of AP for uncomplicated falci-
parum malaria was high, the patients had good tolerance
to AP as shown above, and by taking four tablets as the
total dosage for adults over a 24-hour treatment was
convenient and help to improve patients’ compliance.
Hence, this dosage was recommended for the expanding
clinical trial (Phase III).
Conclusions
In this study, three different forms of ACTs (AP, DHP
and AL) were compared in the multi-drug resistant fal-
ciparum malaria epidemic areas in the Cambodia-Thai-
land border.
T h ed a t af r o mt h i sr e p o r td e m o n s t r a t e dt h a tt h eA P
regimen turned out to be favourable in terms of effi-
cacy and effectiveness, simplicity of administration,
cost and compliance in this particular setting, and it
might play an important role for malaria control in the
near future.
Table 1 Patient age, symptoms, and other clinical measurements
Characteristic Treatment arm
Number of patients AP
(n = 110)
DHP
(n = 55)
AL
(n = 55)
P
value
Gender: Male/Female(ratio) 72/28(2.57) 43/12(3.58) 46/9(5.11) NS
a
Mean age, years(range) 25.2(7-55) 21.9(8-64) 27.4(7-58) NS
Age Groups:
7-10 11(10.0%) 2(3.6%) 5(9.1%) NS
11-15 16(14.54%) 5(9.1%) 5(9.1%) NS
> 15 83(75.46%) 48(87.3%) 45(81.8%) NS
mean duration of fever (in days) (range) 4.2 (1.3-7.1) 4.6 (1.3-7.9) 5.3 (1.1-9.5) NS
Mean parasitaemia
(1 ×/μl)(range)
26637(3801-49473) 25850(195-51505) 31297(1215-61379) NS
Body temperature (°C), mean (range) 38.5(37.7-39.3) 38.8 (37.7-39.9) 38.8(37.7-39.9) NS
Hepatomegly rate (%) 5.5 14.5 7.3 NS
Splenomegly rate (%) 26.4 21.8 12.7 NS
NS: Not significant, P > 0.05
Table 2 Efficacy and parasite clearance time of the three treatment groups
Therapeutic response AP
(n = 110)
DHP
(n = 55)
AL
(n = 55)
Excluded(%) 0 0 0
Lost of follow-up (%) 0 0 0
Early Treatment Failure(%) 0 0 0
Late Clinical Failure(%, 95%CI) 13(11.8, 5.79~17.85%) 1(1.8, -1.71~5.34%) 13(23.6,12.41~34.86%)
ACPR (%, 95% CI)
on D14
on D21
on D28
109 (99.1, 97.31~100.86%)
105(95.5, 91.56%~99.35%)
97(88.2, 82.15%~94.21%)
55(100, 93.6%~100%)
55(100, 93.6%~100%)
54(98.2, 94.65~101.71%)
54(98.2, 94.65~101.71%)
48(87.3, 78.46%~96.08%)
42(76.4, 65.14%~87.59%)
ACPR by Intention-to-treat analysis on D28 (%) 97/110
(88.2)
54/55
(98.2)
42/55
(76.4)
ACPR adjusted by PCR on D28
(%)
97/102*
▲
(95.1)
54/55
(98.2)
42/51
(82.4)
Parasite clearance time, mean ± SD hours 66.7 ± 21.9*
Δ 65.6 ± 27.3
Δ 65.3 ± 22.5
Fever clearance time, mean ± SD hours 31.6 ± 17.7*
Δ 34.6 ± 21.8 36.9 ± 15.4
Note: *P > 0.05, compared with DHP;
▲P < 0.05, compared with AL;
ΔP > 0.05, compared with AL.
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Page 6 of 8Additional material
Additional file 1: Table S1 - Dosing schedules for artemisinin-
piperaquine (AP), dihydroartemisinin-piperaquine phosphate (DHP)
and artemether-lumefantrine (AL). *It is better to take this drug
together with milk and food.
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